The peer-reviewed Journal of Cancer published a positive review of TRPV6 as a cancer therapy target, supporting the potential of closely-held Soricimed’s lead drug candidate, SOR-C13.
TRPV6 plays a role in increasing intracellular calcium and initiating downstream signalling pathways that increase cell proliferation and metastasis, while inhibiting apoptosis, or cell death. The review identifies TRPV6 as a promising drug target in a number of cancers including breast, ovarian, prostate and pancreatic cancer.
Soricimed is developing SOR-C13, the first TRPV6 inhibitor to enter clinical trials, which demonstrated safety and anticancer activity in a Phase 1 clinical trial in late-stage solid tumor cancers. SOR-C13 is currently being tested in a Phase 1b, investigator initiated trial at MD Anderson Cancer Center for the treatment of late-stage pancreatic cancer.
“This article compiles everything we know about TRPV6 – how it works, its mechanism of action as an oncochannel and what controls its gene expression,” Jack Stewart, the publication’s author and Soricimed’s cofounder and CSO, said in a statement.
“In addition to demonstrating TRPV6 as a useful target for solid cancers, this publication outlines how we can exploit TRPV6’s overexpression to treat several cancer types,” he added.
The publication, entitled “TRPV6 as A Target for Cancer Therapy,” is available here.
